Epigenetic modifiers in normal and malignant hematopoiesis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Epigenomics

• Publication date

  2015-05-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2217/epi.14.88PMID 25942537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The controversial role of the Polycomb group proteins in transcription and cancer: how much do we not understand Polycomb proteins?

  2015cited by this paper
• Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies

  2014cited by this paper
• Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

  2014cited by this paper
• Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor

  2014cited by this paper
• Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2.

  2014cited by this paper
• Identification of pre-leukemic hematopoietic stem cells in acute leukemia

  2014cited by this paper
• Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation

  2014cited by this paper
• Variant PRC1 Complex-Dependent H2A Ubiquitylation Drives PRC2 Recruitment and Polycomb Domain Formation

  2014cited by this paper
• Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

  2014cited by this paper
• MMSET: Role and Therapeutic Opportunities in Multiple Myeloma

  2014cited by this paper
• Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies

  2014cited by this paper
• Mll2 is required for H3K4 trimethylation on bivalent promoters in embryonic stem cells, whereas Mll1 is redundant

  2014cited by this paper
• Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro

  2014cited by this paper
• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner.

  2014cited by this paper
• DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells

  2014cited by this paper
• Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.

  2014cited by this paper
• Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.

  2014cited by this paper
• A role for H3K4 monomethylation in gene repression and partitioning of chromatin readers.

  2014cited by this paper
• Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells.

  2014cited by this paper
• The Histone Methyltransferase Activity of MLL1 Is Dispensable for Hematopoiesis and Leukemogenesis

  2014cited by this paper
• DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier

  2014cited by this paper
• AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

  2014cited by this paper
• NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.

  2013cited by this paper
• Automethylation Activities within the Mixed Lineage Leukemia-1 (MLL1) Core Complex Reveal Evidence Supporting a “Two-active Site” Model for Multiple Histone H3 Lysine 4 Methylation*

  2013cited by this paper
• Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

  2013cited by this paper
• The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia

  2013cited by this paper
• The MLL3/MLL4 Branches of the COMPASS Family Function as Major Histone H3K4 Monomethylases at Enhancers

  2013cited by this paper
• The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.

  2013cited by this paper
• Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

  2013cited by this paper
• An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.

  2013cited by this paper
• Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l

  2013cited by this paper
• EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

  2013cited by this paper
• Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation

  2013cited by this paper
• Isocitrate dehydrogenase mutations in leukemia.

  2013cited by this paper
• Promiscuous RNA binding by Polycomb Repressive Complex 2

  2013cited by this paper
• Myeloid Leukemia Cells With MLL partial Tandem Duplication Are Sensitive To Pharmacological Inhibition Of The H3K79 Methyltransferase DOT1L

  2013cited by this paper
• Prognostic score including gene mutations in chronic myelomonocytic leukemia.

  2013cited by this paper
• Mutational landscape and significance across 12 major cancer types

  2013cited by this paper
• (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

  2013cited by this paper
• Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX

  2013cited by this paper
• Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives.

  2013cited by this paper
• Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

  2013cited by this paper
• Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals.

  2013cited by this paper
• BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

  2013cited by this paper
• The Mll2 branch of the COMPASS family regulates bivalent promoters in mouse embryonic stem cells

  2013cited by this paper
• Large conserved domains of low DNA methylation maintained by Dnmt3a

  2013cited by this paper
• An MLL-dependent network sustains hematopoiesis

  2013cited by this paper
• A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells.

  2013cited by this paper
• Self-renewal as a therapeutic target in human colorectal cancer

  2013cited by this paper
• Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia

  2013cited by this paper
• Preclinical Study Of The Bromodomain Inhibitor OTX015 In Acute Myeloid (AML) and Lymphoid (ALL) Leukemias

  2013cited by this paper
• TET1 plays an essential oncogenic role in MLL-rearranged leukemia

  2013cited by this paper
• Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

  2013cited by this paper
• Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer

  2013cited by this paper
• Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders

  2013cited by this paper
• Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.

  2013cited by this paper
• How to use new biology to guide therapy in multiple myeloma.

  2012cited by this paper
• TET2 and DNMT3A mutations in human T-cell lymphoma.

  2012cited by this paper
• Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

  2012cited by this paper
• Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

  2012cited by this paper
• TET2 is essential for survival and hematopoietic stem cell homeostasis

  2012cited by this paper
• Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4.

  2012cited by this paper
• PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes.

  2012cited by this paper
• Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease

  2012cited by this paper
• A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.

  2012cited by this paper
• EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms

  2012cited by this paper
• Polycomb protein Ezh1 promotes RNA polymerase II elongation.

  2012cited by this paper
• Bivalent histone modifications in early embryogenesis.

  2012cited by this paper
• Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation

  2012cited by this paper
• EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent

  2012cited by this paper
• Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia

  2012cited by this paper
• EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex.

  2012cited by this paper
• Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies

  2012cited by this paper
• PRC2 directly methylates GATA4 and represses its transcriptional activity.

  2012cited by this paper
• Progress in understanding 2-hydroxyglutaric acidurias

  2012cited by this paper
• Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.

  2012cited by this paper
• The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

  2012cited by this paper
• Polycomb repressive complex 2 is required for MLL-AF9 leukemia

  2012cited by this paper
• EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

  2012cited by this paper
• Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors.

  2012cited by this paper
• IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

  2012cited by this paper
• TET2 promotes histone O-GlcNAcylation during gene transcription

  2012cited by this paper
• DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

  2012cited by this paper
• A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

  2012cited by this paper
• Polycomb group ring finger 1 cooperates with Runx1 in regulating differentiation and self-renewal of hematopoietic cells.

  2012cited by this paper
• RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3K27me3

  2012cited by this paper
• Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms

  2012cited by this paper
• Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors

  2012cited by this paper
• Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.

  2012cited by this paper
• TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity

  2011cited by this paper
• The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia

  2011cited by this paper
• NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

  2011cited by this paper
• MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.

  2011cited by this paper
• Clinical effect of point mutations in myelodysplastic syndromes.

  2011cited by this paper
• In brief

  2011cited by this paper
• Context-Specific Regulation of NFk B Target Gene Expression by EZH 2 in Breast Cancers

  2011cited by this paper
• Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes

  2011cited by this paper
• MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

  2011cited by this paper
• Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.

  2011cited by this paper

• Histone modifications in the regulation of erythropoiesis

  2025cites this paper
• Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements

  2024cites this paper
• Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors

  2024cites this paper
• Expression of proliferation-related genes in BM-MSC-treated ALL cells in hypoxia condition is regulated under the influence of epigenetic factors in-vitro

  2022cites this paper
• DNA methylation status of DNAJA4 is essential for human erythropoiesis.

  2022cites this paper
• Alternatively Splicing Interactomes Identify Novel Isoform-Specific Partners for NSD2

  2021cites this paper
• Molecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasms and Its Impact on Prognosis and Management

  2021cites this paper
• Childhood Leukemia

  2020cites this paper
• The chromatin remodeler Brg1 is required for formation and maintenance of hematopoietic stem cells

  2020cites this paper
• A regulatory role for CHD2 in myelopoiesis

  2020cites this paper
• Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia

  2019cites this paper
• Dynamic regulation of epigenetic demethylation by oxygen availability and cellular redox

  2019cites this paper
• Long Non-coding RNA in Neuronal Development and Neurological Disorders

  2019cites this paper
• Existing and Emerging Molecular Technologies in Myeloid Neoplasms

  2018cites this paper
• An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy

  2018cites this paper
• Polycomb complexes in normal and malignant hematopoiesis

  2018cites this paper
• Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer.

  2017cites this paper
• Polycomb Proteins in Hematopoiesis and Hematologic Malignancie

  2017cites this paper
• Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis

  2017cites this paper
• Comparison of the Gene Expression Profiles of Human Hematopoietic Stem Cells between Humans and a Humanized Xenograft Model.

  2017cites this paper
• Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia

  2017cites this paper
• Touch, act and go: landing and operating on nucleosomes

  2016cites this paper
• The safety of treatment options for elderly people with acute myeloid leukemia

  2016cites this paper
• Epigenetic Activation of Wnt/β-Catenin Signaling in NAFLD-Associated Hepatocarcinogenesis

  2016cites this paper
• Spotlight on decitabine for myelodysplastic syndromes in Chinese patients

  2015cites this paper
• The role of EVI-1 in normal hematopoiesis and myeloid malignancies (Review).

  2015cites this paper